Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction

PURPOSE: Paclitaxel-based chemotherapy continues to be an integral component in the treatment of many solid tumors. Prolonged use of paclitaxel may result in repeated doses of premedications and potential unwanted side effects. Infusion hypersensitivity reactions occurring beyond the second dose are...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Michael J., Dunlea, Leslie J., Rettig, Amy E., Lustberg, Maryam B., Phillips, Gary S., Shapiro, Charles L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411299/
https://www.ncbi.nlm.nih.gov/pubmed/22089428
http://dx.doi.org/10.1007/s00520-011-1303-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411299/
https://www.ncbi.nlm.nih.gov/pubmed/22089428
http://dx.doi.org/10.1007/s00520-011-1303-9

Ejemplares similares